After-Hours, AstraZeneca

AstraZeneca stock closes at GBX 12,552.00 on September 25, 2026

Published on 09/28/2026 at 23:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AstraZeneca shares closed at GBX 12,552.00 on September 25, 2026, up 1.23 percent. The company also reported that its SERENA-4 trial missed its primary endpoint.

Wissenschaftler im weißen Kittel arbeiten in modernem Pharma-Forschungslabor
AstraZeneca plc (ISIN GB0009895292) betreibt moderne Forschungslabore für pharmazeutische Wirkstoffentwicklung und klinische Studien weltweit, Illustration mit AI erstellt.

Trading session

AstraZeneca PLC shares closed at GBX 12,552.00 on the London Stock Exchange on September 25, 2026, up 1.23 percent from the previous session.

Clinical development

In a September 11, 2026 announcement, AstraZeneca said its SERENA-4 Phase III trial of Etcamah, or camizestrant, combined with palbociclib did not meet its primary endpoint of statistically significant improvement in progression-free survival. The company said a numerical improvement was observed.

The trial evaluated the combination against anastrozole combined with palbociclib in patients with estrogen receptor-positive, HER2-negative advanced breast cancer who had not received systemic treatment for advanced disease. AstraZeneca said the global trial enrolled 1,371 adults and that the safety profile was consistent with the known safety profile of each medicine, with no new safety concerns identified.

Disclaimer...

en | boerse | 70195603 |